Farbod Shojaei

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. ncbi Anti-angiogenesis therapy in cancer: current challenges and future perspectives
    Farbod Shojaei
    Oncology Research Unit, Pfizer La Jolla, CA 92121, United States
    Cancer Lett 320:130-7. 2012
  2. doi HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis
    Farbod Shojaei
    Oncology Research Unit, Pfizer La Jolla, CA 92121, United States
    Cancer Lett 320:48-55. 2012
  3. doi HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors
    Farbod Shojaei
    Oncology Research Unit, Pfizer, La Jolla, California, USA
    Cancer Res 70:10090-100. 2010
  4. doi Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) mice
    Brett H Simmons
    Oncology Research Unit, Pfizer Global R and D, San Diego, CA 92121, USA
    Cancer Chemother Pharmacol 70:213-20. 2012
  5. pmc Contrast agents for quantitative microCT of lung tumors in mice
    Kush Lalwani
    Comparative Medicine, Pfizer, San Diego, California, USA
    Comp Med 63:482-90. 2013
  6. pmc Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer
    Farbod Shojaei
    Pfizer Global Research and Development, Department of Oncology, La Jolla, CA, USA
    J Exp Clin Cancer Res 31:26. 2012

Collaborators

  • Nathan Scott
  • Kush Lalwani
  • Anthony Wong
  • Patrick B Lappin
  • Jeetendra Eswaraka
  • Anand Giddabasappa
  • Brett H Simmons
  • Todd Van Arsdale
  • Peter Olson
  • Brett Simmons
  • Danan Li
  • James Christensen
  • Amy Jackson-Fisher
  • James G Christensen
  • Julie L Kan
  • Brittany A Snider
  • Joseph H Lee

Detail Information

Publications6

  1. ncbi Anti-angiogenesis therapy in cancer: current challenges and future perspectives
    Farbod Shojaei
    Oncology Research Unit, Pfizer La Jolla, CA 92121, United States
    Cancer Lett 320:130-7. 2012
    ..Investigations in clinic and preclinical models have provided some molecular and cellular mechanisms for the above challenges. This review aims to provide a concise update from recent findings...
  2. doi HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis
    Farbod Shojaei
    Oncology Research Unit, Pfizer La Jolla, CA 92121, United States
    Cancer Lett 320:48-55. 2012
    ..In conclusion, our findings indicate that sunitinib-induced metastasis is tumor cell-type dependent and further supports a rationale for combination of anti-angiogenics and c-Met inhibition in the clinic...
  3. doi HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors
    Farbod Shojaei
    Oncology Research Unit, Pfizer, La Jolla, California, USA
    Cancer Res 70:10090-100. 2010
    ....
  4. doi Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) mice
    Brett H Simmons
    Oncology Research Unit, Pfizer Global R and D, San Diego, CA 92121, USA
    Cancer Chemother Pharmacol 70:213-20. 2012
    ..In conclusion, our data suggest that PD-0325901 at doses below MTD is still a potent compound capable of tumor growth inhibition where Kras and/or PI3K are drivers of tumor growth and progression...
  5. pmc Contrast agents for quantitative microCT of lung tumors in mice
    Kush Lalwani
    Comparative Medicine, Pfizer, San Diego, California, USA
    Comp Med 63:482-90. 2013
    ..Contrast-enhanced ╬╝CT imaging is an excellent noninvasive method for longitudinal evaluation during preclinical lung tumor studies. ..
  6. pmc Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer
    Farbod Shojaei
    Pfizer Global Research and Development, Department of Oncology, La Jolla, CA, USA
    J Exp Clin Cancer Res 31:26. 2012
    ....